Literature DB >> 17391171

PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.

H-J Lüddeke1, S Sreenan, S Aczel, S Maxeiner, M Yenigun, P Kozlovski, H Gydesen, A Dornhorst.   

Abstract

AIM: PREDICTIVEtrade mark (Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation) is a large, multi-national, observational study assessing the safety and efficacy of insulin detemir. We report the study design, population characteristics and baseline observations, including cross-sectional analysis, from 19 911 patients with type 1 or 2 diabetes.
METHODS: Patients with type 1 or 2 diabetes requiring basal insulin are prescribed insulin detemir and followed up for 12-52 weeks. Data on demographics, haemoglobin A(1c) (HbA(1c)), fasting glucose, within-subject fasting glucose variability and weight are collected from patient records (and/or recall for hypoglycaemia). A negative binomial distribution model is used to assess the influence of predictive/confounding variables on hypoglycaemic episodes in insulin-treated patients at baseline. Multi-factorial analysis of covariance is used to evaluate the association of the variables with current body weight and within-subject fasting glucose variability.
RESULTS: Total hypoglycaemic episodes in the 4 weeks prior to study start were 47.5 per patient-year in patients with type 1 and 9.2 per patient-year in patients with type 2 diabetes. The frequency of hypoglycaemia in insulin-treated patients showed a significant, positive association with duration of diabetes, number of insulin injections and fasting glucose variability but was inversely related to HbA(1c), fasting glucose and body mass index. Weight showed a significant positive association with gender (male > female) and insulin dosage. Weight was also positively associated with fasting glucose variability in patients with type 1 diabetes, and age and number of injections in patients with type 2 diabetes.
CONCLUSIONS: These baseline data showed that, in addition to the established relationship with intensive treatment and HbA(1c), frequency of hypoglycaemia was positively associated with fasting glucose variability. Follow-up data from PREDICTIVE will provide insights on insulin detemir in diabetes management.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391171     DOI: 10.1111/j.1463-1326.2006.00677.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  27 in total

Review 1.  Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

Authors:  Ulrik Pedersen-Bjergaard; Birger Thorsteinsson
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

2.  Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study.

Authors:  Werner Kern; Andreas Holstein; Christian Moenninghoff; Joachim Kienhöfer; Matthias Riedl; Bernhard Kulzer
Journal:  Exp Clin Endocrinol Diabetes       Date:  2017-07-27       Impact factor: 2.949

3.  A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes.

Authors:  J Hans DeVries; Luigi Meneghini; Anthony H Barnett; Timothy Reid; Marie-Paule Dain; Wolfgang Landgraf; Aleksandra Vlajnic; Louise Traylor; Richard M Bergenstal
Journal:  Eur Endocrinol       Date:  2014-02-28

4.  3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study.

Authors:  Kjeld Hermansen; Per Lund; Kurt Clemmensen; Leif Breum; Marianne Kleis Moller; Anne Mette Rosenfalck; Erik Christiansen
Journal:  Rev Diabet Stud       Date:  2007-08-10

Review 5.  The role of insulin detemir in overweight type 2 diabetes management.

Authors:  Yared N Demssie; Naveed Younis; Handrean Soran
Journal:  Vasc Health Risk Manag       Date:  2009-06-29

6.  Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.

Authors:  Plamen Kozlovski; James Foley; Qing Shao; Valentina Lukashevich; Wolfgang Kothny
Journal:  World J Diabetes       Date:  2013-08-15

Review 7.  Defining the role of insulin detemir in Basal insulin therapy.

Authors:  Javier Morales
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Insulin detemir: a review of its use in the management of diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

Review 9.  Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Xiaoling Cai; Chu Lin; Wenjia Yang; Lin Nie; Linong Ji
Journal:  Diabetes Metab J       Date:  2021-03-15       Impact factor: 5.376

10.  Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes.

Authors:  Athena Philis-Tsimikas
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.